Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients - PubMed (original) (raw)

doi: 10.1038/s41598-017-10034-5.

Cristina Piras 1, Antonio Murgia 2, Vanessa Palmas 1, Tania Camboni 1, Sonia Liggi 1, Ivan Ibba 3, Maria Antonia Lai 4, Sandro Orrù 3, Sylvain Blois 1, Anna Lisa Loizedda 5, Julian Leether Griffin 6, Paolo Usai 3, Pierluigi Caboni 2, Luigi Atzori 1, Aldo Manzin 7

Affiliations

Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients

Maria Laura Santoru et al. Sci Rep. 2017.

Erratum in

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract of uncertain origin, which includes ulcerative colitis (UC) and Crohn's disease (CD). The composition of gut microbiota may change in IBD affected individuals, but whether dysbiosis is the cause or the consequence of inflammatory processes in the intestinal tissue is still unclear. Here, the composition of the microbiota and the metabolites in stool of 183 subjects (82 UC, 50 CD, and 51 healthy controls) were determined. The metabolites content and the microbiological profiles were significantly different between IBD and healthy subjects. In the IBD group, Firmicutes, Proteobacteria, Verrucomicrobia, and Fusobacteria were significantly increased, whereas Bacteroidetes and Cyanobacteria were decreased. At genus level Escherichia, Faecalibacterium, Streptococcus, Sutterella and Veillonella were increased, whereas Bacteroides, Flavobacterium, and Oscillospira decreased. Various metabolites including biogenic amines, amino acids, lipids, were significantly increased in IBD, while others, such as two B group vitamins, were decreased in IBD compared to healthy subjects. This study underlines the potential role of an inter-omics approach in understanding the metabolic pathways involved in IBD. The combined evaluation of metabolites and fecal microbiome can be useful to discriminate between healthy subjects and patients with IBD.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1

Figure 1

Microbiome taxonomic composition in IBD, CD, UC patients and control subjects (CTLs). Relative abundance at OTU frequency at phylum level, Firmicutes/Bacteroidetes ratio, and α-diversity are shown. The data are filtered by a frequency higher than 0.1% (a). Relative abundance of phyla and OTU frequency are shown in CD (*) (b) and UC (*) (c) patients compared to controls (CTLs, ^). Significant differences with p < 0.05 are shown. *patients; ^controls.

Figure 2

Figure 2

Microbiome taxonomic composition at genus level in CD, UC and controls subjects. Relative abundance of genera and OTU frequency are shown in CD (*) and UC (*) patients compared to controls (CTLs, ^). Significant differences with p < 0.05 are shown.

Figure 3

Figure 3

Relative abundance of species in CD e UC patients compared to controls subjects. OTU frequency of species higher than 0.01% are indicated as expanded or contracted in patients groups and controls subjects. *Indicates that only levels of significance with p < 0.05 for the species indicated are shown.

Figure 4

Figure 4

OPLS-DA score plots. In the first column CD vs healthy comparisons are shown while the second column of plots contains UC vs healthy comparisons. Plots were obtained with GC-MS (a,b), 1H-NMR (c,d) and LC-MS/MS QTOF analysis (e,f).

Figure 5

Figure 5

Statistically significant metabolites in CD vs healthy comparison. Discriminant metabolites obtained with the MVA, underwent to a Mann-Whitney test to determine which metabolites were statistically significantly variated. The resulted metabolites obtained are shown. Relative concentrations are represented in the y axis. * And **Indicates levels of significance with p < 0.05 and <0.01, respectively.

Figure 6

Figure 6

Statistically significant metabolites in UC vs healthy comparison. Discriminant metabolites obtained with the MVA, underwent to a Mann-Whitney test to determine which metabolites were statistically significantly variated. The resulted metabolites obtained are shown. Relative concentrations are represented in the y axis. * And **Indicates levels of significance with p < 0.05 and <0.01, respectively.

Figure 7

Figure 7

Relevant metabolic pathways involved in CD (a) and in UC (b).

Figure 8

Figure 8

Inter-omic Spearman rank correlation between metabolites and bacterial genera and species. Spearman correlation between statistically different metabolites and bacterial genera was calculated both for CD (a) and UC (b). Spearman correlation between statistically different metabolites and bacterial species was calculated both for CD (c) and UC (d). Correlations with an r coefficient >0.5 are shown.

References

    1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nat. 2007;448:427–434. doi: 10.1038/nature06005. - DOI - PubMed
    1. Gunesh S, et al. The incidence of Crohn’s disease in Cardiff over the last 75 years: an update for 1996–2005. Alim Pharm Ther. 2008;27(3):211–219. doi: 10.1111/j.1365-2036.2007.03576.x. - DOI - PubMed
    1. Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol. 2012;142(1):46–54. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed
    1. Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol. 2006;101(5):993–1002. doi: 10.1111/j.1572-0241.2006.00381.x. - DOI - PubMed
    1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627–1640. doi: 10.1016/S0140-6736(07)60750-8. - DOI - PubMed

Publication types

Grants and funding

LinkOut - more resources